

Fixed Drug Eruption due to Linezolid

Sir,

Linezolid is the first synthetic antibiotic belonging to the class “oxazolidinones” approved by the United States Food and Drug Administration.^[1] It has a wide spectrum of antibacterial activity, especially in multidrug-resistant organisms. The ones of dermatological interest are skin and soft-tissue infections caused by (a) methicillin-resistant *Staphylococcus aureus* (MRSA) and (b)

vancomycin-resistant *S. aureus*/heterogeneous vancomycin intermediate *S. aureus*.^[1,2] In the wake of both hospital- and community-acquired MRSA, the use of linezolid is on the rise among various medical specialties. It is convenient to use as both oral (100% bioavailability) and parenteral preparations are available, good tissue penetration, and well tolerated by patients and relatively infrequent adverse effects with short-term usage.^[2]




Figure 1: Two discrete slate-colored macules with surrounding erythema on the left thumb.

A 45-year-old nondiabetic male consulted a dermatologist for a minimally pruritic hyperpigmented lesion on the left thumb. He took treatment for perianal abscess caused by MRSA sensitive to linezolid. He was advised tablet linezolid (600 mg PO × bd) along with tablet diclofenac sodium (50 mg PO × bd) for 14 days. After 10 days of drug intake, he developed minimal pruritus on lateral aspect of the pulp of the left thumb followed by development of an oval, slate-colored patch (1 cm × 1 cm). A diagnosis of fixed drug eruption (FDE) was made, but the causative drug could not be pin-pointed. He was advised to stop both the drugs. Betamethasone dipropionate ointment was prescribed for topical application on the lesion and was asked to follow up.

The patient missed the follow-up visit but came after 1½ months with a new similar patch below the earlier one, with surrounding erythema [Figure 1]. At the same time, there was darkening of the earlier lesion and associated pruritus. The patient admitted that he was self-medicating with tablet linezolid for the past 7 days for a fresh abscess in the perineum. No other medication was taken this time. Linezolid was stopped and the patient was counseled regarding harms of self-medication and about chance of recurrence of the lesion with repeated insult.

A diagnosis of recurrent FDE due to linezolid was made. The adverse reaction spectrum of linezolid is mostly systemic.^[1] The common side effects are nausea, diarrhea, and headache.^[2] The severe ones are myelosuppression causing pancytopenia, thrombocytopenia, optic and peripheral neuropathy, lactic acidosis, and anaphylactoid-like reactions.^[1,2] Rarely, elevation of serum transaminases and creatinine level may be seen.^[1,2] All the side effects of linezolid are usually encountered with prolonged use (more than 2 weeks) and are reversible on withdrawal of the drug.^[3] A rare drug interaction is “serotonin syndrome,” if there is accidental co-prescription with selective serotonin reuptake inhibitors.^[1]

Common cutaneous adverse effects related to linezolid known so far from published English literature are pruritus, macular exanthema, and maculopapular rash.^[1,2] Other anecdotal reports include angioedema,^[3] drug rash with eosinophilia and systemic symptoms,^[4] and leukocytoclastic vasculitis.^[5] FDE caused by linezolid has not been reported so far. The list of drugs causing FDE is long and ever-increasing with the use of newer molecules. This case with FDE due to linezolid is a new addition to the list.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Arun C Inamadar, Aparna Palit

Department of Dermatology, Venereology and Leprosy, Shri B M Patil Medical College Hospital and Research Center, BLDE University, Vijaypur, Karnataka, India


Address for correspondence:

Prof. Arun C Inamadar, Department of Dermatology, Venereology and Leprosy, Shri B M Patil Medical College Hospital and Research Center, BLDE University, Vijaypur - 586 103, Karnataka, India. E-Mail: aruninamadar@gmail.com

REFERENCES

1. Kim S, Michaels BD, Kim GK, Del Rosso JQ. Systemic antibacterial agents. In: Wolverson SE, editor. *Comprehensive Dermatologic Drug Therapy*. 3rd ed. Philadelphia: Elsevier, Saunders; 2013. p. 61-97.
2. Diekema DJ, Jones RN. Oxazolidinone antibiotics. *Lancet* 2001;358:1975-82.
3. Vardakas KZ, Ntziora F, Falagas ME. Linezolid: Effectiveness and safety for approved and off-label indications. *Expert Opin Pharmacother* 2007;8:2381-400.
4. Savard S, Desmeules S, Riopel J, Agharazii M. Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. *Am J Kidney Dis* 2009;54:e17-20.
5. Sathyannarayana V, Das U, Babu KG, Suresh TM, Suresh Babu, Lakshmaiah KC, *et al.* Linezolid induced vasculitis: An unusual case report with review of the literature. *J Sci Soc* 2015;42:27-30.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code: 	Website: www.ijdd.in
	DOI: 10.4103/ijdd.ijdd_8_17

How to cite this article: Inamadar AC, Palit A. Fixed drug eruption due to linezolid. *Indian J Drugs Dermatol* 2017;3:38-9.

© 2017 Indian Journal of Drugs in Dermatology | Published by Wolters Kluwer - Medknow